Quarterly ResultAug 10, 2026, 04:40 PM

Perspective Therapeutics Q2 Net Loss $26.8M; Cash $237M

AI Summary

Perspective Therapeutics reported a net loss of $26.8 million, or $0.22 per share, for the second quarter ended June 30, 2026. The company held approximately $237 million in cash, cash equivalents, and short-term investments, which is expected to fund operations into late 2027. Key business highlights include advancing VMT-α-NET toward a Phase 3 study in neuroendocrine tumors, with site activation targeted around year-end 2026, and continued progress in other clinical programs. The company also announced manufacturing expansion plans and a new Chief Science Officer.

Key Highlights

Cash, cash equivalents, and short-term investments totaled $237 million as of June 30, 2026.
Net loss for Q2 2026 was $26.8 million, or $0.22 per basic and diluted share.
Research and development expenses increased to $21.5 million in Q2 2026 from $16.6 million in Q2 2025.
General and administrative expenses were $7.8 million in Q2 2026, up from $7.7 million in Q2 2025.
VMT-α-NET is advancing toward a Phase 3 study, with site activation targeted around year-end 2026.
Cash runway is expected to be sufficient to fund operations into late 2027.
Chicago manufacturing facility construction is expected to complete in early 2027.
Paul Lyne, Ph.D. was appointed Chief Science Officer in July 2026.

View SEC Filing

CATX

Medical/Dental Instruments

Perspective Therapeutics, Inc.

Price Impact